Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17485268 | 1.00 | MAPT (0.63) | MAPTPKMSLC6A3SLC18A2MEN1 | |
| SCHEMBL17486608 | 0.90 | MAPT (0.60) | MAPTPKMSLC6A3SLC18A2MEN1 | |
| SCHEMBL7674949 | 0.90 | MAPT (0.60) | MAPTPKMSLC6A3SLC18A2MEN1 | |
| SCHEMBL7674955 | 0.90 | MAPT (0.60) | MAPTPKMSLC6A3SLC18A2MEN1 | |
| SCHEMBL7674961 | 0.90 | MAPT (0.60) | MAPTPKMSLC6A3SLC18A2MEN1 | |
| SCHEMBL17485211 | 0.90 | MAPT (0.60) | MAPTPKMSLC6A3SLC18A2MEN1 | |
| SCHEMBL17477235 | 0.90 | MAPT (0.60) | MAPTPKMSLC6A3SLC18A2MEN1 | |
| SCHEMBL17485186 | 0.90 | MAPT (0.60) | MAPTPKMSLC6A3SLC18A2MEN1 | |
| SCHEMBL17485168 | 0.90 | MAPT (0.60) | MAPTPKMSLC6A3KCNH2REN | |
| SCHEMBL19483128 | 0.89 | MAPT (0.79) | MAPTPKMSLC6A3SLC18A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-10-19 | — | — | US | disclosed |
| US-9546151-B2 | VMAT inhibitory compounds | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160031852-A1 | VMAT INHIBITORY COMPOUNDS | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | SLC18A2, SLC18A3, SLC6A2 | MAPT 259/4885PKM 809/4885SLC6A3 4/4885 |
| US-20160031852-A1 | VMAT INHIBITORY COMPOUNDS | SLC18A2, SLC18A3, SLC6A2 | MAPT 259/4885PKM 809/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.